Breast Cancer Trial, Recruiting (NCT07273812)

Breast Cancer Trial, Recruiting NCT07273812 Sponsor: Dena h. Al-Tameemi Condition: Breast Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07273812 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Breast Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have a confirmed diagnosis of breast cancer at stage I, II, or III
People who are about to start their very first round of chemotherapy
People who are 18 years of age or older
People who are able to understand the study and agree to take part by signing a consent form
People who own a smartphone (Android or Apple) and are comfortable using mobile apps, reading on-screen text in Arabic, and entering daily health information into an app (this applies to the active treatment group)
People who are willing to follow the study's procedures and attend follow-up appointments
People who are able to communicate in Arabic, as the app and chatbot used in this study are in Arabic

Who may not be able to join:

People who have stage IV (metastatic) breast cancer, meaning cancer that has spread to other parts of the body
People who are receiving hormonal therapy at the same time as chemotherapy during the study period
People who have significant memory, thinking, or severe mental health difficulties that would make it hard to use the mobile app or complete questionnaires (confirm with trial site)
People who are receiving palliative (comfort-focused) care only, where chemotherapy is not being given with the goal of treating or extending life
People who are already taking part in another clinical trial that involves a treatment or intervention
People who have serious other health conditions that could significantly affect their ability to take part or influence the study results (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Samer Imad Mohammed, Assistant Prof, University of Baghdad-College of Pharmacy

Phone: +9647901572647

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07273812

Sponsor: Dena h. Al-Tameemi

Phase: Not Applicable

Status: Recruiting

Condition: Breast Cancer

Trial contact: +9647901572647

More information: https://clinicaltrials.gov/study/NCT07273812

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have a confirmed diagnosis of breast cancer at stage I, II, or III
People who are about to start their very first round of chemotherapy
People who are 18 years of age or older
People who are able to understand the study and agree to take part by signing a consent form
People who own a smartphone (Android or Apple) and are comfortable using mobile apps, reading on-screen text in Arabic, and entering daily health information into an app (this applies to the active treatment group)
People who are willing to follow the study's procedures and attend follow-up appointments
People who are able to communicate in Arabic, as the app and chatbot used in this study are in Arabic

Who may not be able to join:

People who have stage IV (metastatic) breast cancer, meaning cancer that has spread to other parts of the body
People who are receiving hormonal therapy at the same time as chemotherapy during the study period
People who have significant memory, thinking, or severe mental health difficulties that would make it hard to use the mobile app or complete questionnaires (confirm with trial site)
People who are receiving palliative (comfort-focused) care only, where chemotherapy is not being given with the goal of treating or extending life
People who are already taking part in another clinical trial that involves a treatment or intervention
People who have serious other health conditions that could significantly affect their ability to take part or influence the study results (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Dena h. Al-Tameemi

Registry

ClinicalTrials.gov

Start date

1 June 2026

Est. completion

6 August 2026

Where this trial is recruiting

Iraq

Primary endpoints

Change in Symptom Burden and Chemotherapy-Related Toxicities (Arabic PRO-CTCAE); Medication Adherence Score (Arabic MMAS-8; Change in Patient Knowledge and Information Satisfaction (EORTC QLQ-INFO25); Change in General Quality of Life (EORTC QLQ-C30); Change in Breast Cancer-Specific Quality of Life (EORTC QLQ-BR23)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov